MiraMSC-FS-001

Phase 1

MMiracle Biomedical Co., Ltd.

MiraMSC-FS-001 is one of 2 therapeutic programs targeting Frailty. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

FrailtyNot yet recruiting

FrailtyPhase 1

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Frailty

#DrugCompanyPhaseTrials

Mitoquinone Mesylate

AAntipodean Pharmaceuticals, Inc.

Phase 2

1 2

MiraMSC-FS-001

MMiracle Biomedical Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Not yet recruiting

Frailty

NCT07705464

Clinical

Trials by Indication[1]

Frailty1 trial

A Phase I, Open-Label Study to Evaluate the Safety and Tolerability of MiraMSC Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome

Not yet recruiting·MMiracle Biomedical Co., Ltd.·Phase 1·NCT07705464·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MiraMSC-FS-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for MiraMSC-FS-001. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Miracle Biomedical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: MMiracle Biomedical Co., Ltd.

MiraMSC-FS-001

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Frailty1 trial

References

Drug Info

Quick Facts

Related News